Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
-
Published:2019-11
Issue:
Volume:121
Page:144-153
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Schadendorf DirkORCID, Ascierto Paolo A., Haanen John, Espinosa Enrique, Demidov Lev, Garbe Claus, Guida Michele, Lorigan PaulORCID, Chiarion-Sileni Vanna, Gogas Helen, Maio Michele, Fierro Maria Teresa, Hoeller Christoph, Terheyden Patrick, Gutzmer Ralf, Guren Tormod K., Bafaloukos Dimitrios, Rutkowski PiotrORCID, Plummer Ruth, Waterston Ashita, Kaatz Martin, Mandala Mario, Marquez-Rodas Ivan, Muñoz-Couselo Eva, Dummer Reinhard, Grigoryeva Elena, Young Tina C., Nathan Paul
Funder
Bristol-Myers Squibb Novartis Roche MSD/Merck Amgen Merck-EMD Pierre Fabre Philogen Incyte
Subject
Cancer Research,Oncology
Reference20 articles.
1. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat Rev Clin Oncol,2017 2. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015 3. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial;Larkin;J Clin Oncol,2018 4. Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): results from a phase II study (CheckMate 172);Schadendorf;J Clin Oncol,2017 5. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172);Nathan;Eur J Cancer,2019
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|